
Redeye Initiates Coverage of NextCell Pharma

Redeye initiates coverage of NextCell Pharma, a clinical-stage biotech company developing a cell therapy with disease-modifying potential in type 1 diabetes. Strong clinical data and upcoming phase II readouts in 2025–2026 could pave the way for an outlicensing deal, yet the valuation remains modest—offering a compelling opportunity.

[Read more and download the Research Report.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

[Redeye Initiates Coverage of NextCell Pharma](#)